Richard Fisher
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Medicine |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
|
|---|
|
|
|
| Title | Med Ctr Vice President for Strategic & Program Dev. |
|---|
| Institution | University of Rochester Medical Center |
|---|
| Department | Office of VP for Health Sciences |
|---|
|
|
|---|
|
| 1970 |
|
| M.D. Cum Laude | | 1984 |
|
| Fellow
American College of Physicians | | 1984 |
|
| Outstanding Unit Citation for Studies of Diffuse Aggressive Lymphomas
United States Public Health Service, Department of Health and Human Services | | 1985 |
|
| Board of Governors
Southwest Oncology Group | | 1985 |
|
| Chairman, Lymphoma Committee
Southwest Oncology Group | | 1988 |
-
| 1989 | Chairman
Medical Research Advisory Group A, Veterans Administration | | 1988 |
-
| 1989 | Program Committee, Chairman, Lymphomas, Leukemia, Pediatrics Section
American Society of Clinical Oncology | | 1988 |
-
| 1989 | Board of Directors
American Society of Clinical Oncology | | 1989 |
-
| 1990 | Chairman, Industry (Exhibits) Advisory Committee
American Society of Clinical Oncology | | 1990 |
-
| 1991 | Chairman, Young Investigator's Award Committee
American Society of Clinical Oncology | | 1990 |
|
| Visiting Professor
Cleveland Clinic | | 1990 |
|
| Masters in Oncology Lecture Series
University of Wisconsin Cancer Center | | 1991 |
-
| 2000 | Chairman, External Advisory Committee
Prentis Comprehensive Cancer Center, Michigan Cancer Foundation and Wayne State University | | 1991 |
|
| Paul Jackson Rogers Memorial Lectureship
Texas A & M University College of Medicine | | 1992 |
|
| The Best Cancer Specialists in the U.S.
Good Housekeeping Magazine | | 1993 |
|
| Director
Southwest Oncology Group Foundation | | 1993 |
|
| Bertha A. Bouroncle Keynote Lecture
The Ohio State University | | 1993 |
|
| Masters in Oncology Lecture Series
University of Wisconsin Cancer Center | | 1995 |
|
| Chairman, NIH Special Review Committee for AIDS-Associated Malignancies Clinical Trial Consortium | | 1996 |
|
| Classic Paper: Highlights of Clinical Lymphoma Research (Reference # 157)
Selected by Journal of Clinical Oncology | | 1996 |
|
| The Best Doctors in America
American Health Magazine | | 1997 |
-
| 2001 | Member, NCI Scientific Review Group, Subcommittee H | | 1997 |
|
| Japanese Society of Lymphoreticular Malignancy Keynote Lecture | | 1998 |
-
| 2001 | Member, Board of Directors
Cure for Lymphoma Foundation | | 1999 |
-
| 2001 | External Advisory Board
Barrett Cancer Center, University of Cincinnati | | 1999 |
|
| The Best Doctors in America
Castle Connolly Medical Publications | | 2000 |
-
| 2002 | President, Faculty Senate
Loyola University Stritch School of Medicine | | 2000 |
-
| 2001 | Member, Lymphoma Research Foundation of America's Honorary Medical Board | | 2000 |
-
| 2005 | Member, External Advisory Board
San Antonio Cancer Institute | | 2001 |
|
| Member, Lymphoma Research Foundation
Scientific Advisory Board | | 2001 |
|
| Toni Thompson Memorial Lectureship in Oncology
University of Oklahoma, Oklahoma City, OK | | 2001 |
|
| Derrick Crowther Lecturer
Cologne, Germany | | 2002 |
|
| George P. Canellos Lecture in Medical Oncology
Dana Farber Cancer Institute, Harvard | | 2002 |
|
| Board of Directors, Harvard Club of Rochester | | 2003 |
-
| 2005 | Vice President
Harvard Club of Rochester | | 2003 |
|
| Honorary Chair
American Cancer Society Walter Hagen Golf Tournament | | 2004 |
|
| Alan J. Underberg Lecture
University of Rochester | | 2005 |
|
| External Advisory Board
Yale University Cancer Center | | 2005 |
|
| Deputy Group Chair
Southwest Oncology Group | | 2005 |
|
| President
Harvard Club of Rochester | | 2005 |
|
| Grinberg/Wisch Endowed Visiting Lectureship in Hematology/Oncology
Mount Sinai School of Medicine | | 2005 |
|
| Vice President, Hope Foundation | | 2005 |
|
| Dept. Group Chair | Southwest Oncology Group | | 2006 |
|
| Davey Memorial Award for Outstanding Cancer Research | | 2007 |
|
| Member, University of Rochester Medical Center Board | | 2007 |
|
| ASCO Statesman Award, American Society of Clinical Oncology | | 2009 |
|
| Freundlich Leadership Award, Lymphoma Research Foundation | | 2012 |
|
| Fellow of the American Society of Clinical Oncology |
Richard I. Fisher, M.D. is a visionary that never loses sight of his patients. His greatest desire as Director of the Wilmot Cancer Center is to build a world-class cancer research and treatment facility that will provide advanced care and the most modern treatments for patients with cancer. With great concern and enthusiasm, he intends to ensure that patients get cutting-edge care as our cancer research program develops the treatments that will benefit patients around the world.
Dr. Fisher is an internationally known expert in biological research and treatment of lymphoma and is a nationally renowned cancer clinician, scientist and educator. His research centers on the biology and treatment of cancers derived from white blood cells. Dr. Fisher leads both national and international studies in Hodgkin's Disease and Non-Hodgkin's lymphoma.
Contact:
Richard I. Fisher, M.D.
University of Rochester Cancer Center
601 Elmwood Avenue
Box 704
Rochester, NY 14642
For referrals, call 1-866-4WILMOT
-
Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. J Clin Oncol. 2013 Jan 20; 31(3):314-20.
-
Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012 Oct 18; 120(16):3280-7.
-
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012 Aug 12; 490(7418):116-20.
-
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, Leblanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 2013 Jan 15; 119(2):371-9.
-
Stopeck AT, Unger JM, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012 Aug 9; 120(6):1210-7.
-
Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo. Mol Cancer Ther. 2012 May; 11(5):1122-32.
-
Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2012 Apr 15; 18(8):2210-9.
-
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012 Jun; 97(6):937-42.
-
Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, Fisher RI. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012 Feb; 53(2):259-62.
-
Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, Constine L, Becker M, Phillips G, Liesveld J, Fisher RI, Bernstein SH, Friedberg JW. Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era. Biol Blood Marrow Transplant. 2012 Apr; 18(4):640-7.
-
Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep; 10(9):1686-97.
-
Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2011 May 10; 29(14):1876-84.
-
Fisher RI. Advanced insights into the biology of malignant lymphomas. J Clin Oncol. 2011 May 10; 29(14):1799-800.
-
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10; 117(10):2807-12.
-
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3; 470(7332):115-9.
-
Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010 Oct; 151(2):143-51.
-
Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J, Vose J, Wolff SN, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011 Jan; 17(1):20-47.e30.
-
Goy A, Bernstein SH, McDonald A, Pickard MD, Shi H, Fleming MD, Bryant B, Trepicchio W, Fisher RI, Boral AL, Mulligan G. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma. 2010 Jul; 51(7):1269-77.
-
Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010 Apr 15; 16(8):2435-42.
-
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010 Jun 3; 115(22):4478-87.
-
Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res. 2010 Mar; 34(3):379-86.
-
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan 7; 463(7277):88-92.
-
Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol. 2010 Jun; 21(6):1196-202.
-
Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2010 May 1; 77(1):79-85.
-
Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009 Aug; 9(4):307-10.
-
Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug; 146(3):282-91.
-
Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther. 2009 May; 8(9):808-19.
-
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma. 2009 May; 50(5):728-35.
-
Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.
-
Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009 Apr 16; 113(16):3809-12.
-
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009 Mar; 20(3):520-5.
-
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1; 27(1):114-9.
-
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008 Nov 27; 359(22):2313-23.
-
Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008 Oct; 22(5):941-52, ix.
-
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008 Sep 9; 105(36):13520-5.
-
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008 Jul 27; 86(2):215-22.
-
Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008 Oct; 19(10):1759-64.
-
Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 2008 May; 26(4):431-3.
-
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008 May 10; 26(14):2258-63.
-
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008 Mar 21; 319(5870):1676-9.
-
Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008 Apr 15; 111(8):4048-54.
-
Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007 Mar 19; 204(3):633-43.
-
Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007 Jun 1; 109(11):4599-606.
-
Schaefer-Cutillo J, Friedberg JW, Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park). 2007 Feb; 21(2):203-12; discussion 214, 217, 221.
-
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10; 25(5):579-86.
-
Fisher RI. Treatment of diffuse large B-cell lymphomas. Semin Hematol. 2006 Oct; 43(4):205-6.
-
Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007 Feb; 122(2):139-45.
-
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct 20; 24(30):4867-74.
-
Fisher SG, Fisher RI. The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol. 2006 Sep; 18(5):417-24.
-
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006 Sep 1; 24(25):4143-9.
-
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006 Jun 8; 354(23):2431-42.
-
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1; 24(19):3121-7.
-
Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, Francis CW. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Jun; 47(6):1029-33.
-
Fisher RI, Coiffier B, Vose JM. Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas. Clin Adv Hematol Oncol. 2006 Apr; 4(4):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10.
-
Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006 Jun 1; 107(11):4207-13.
-
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006 Jan 20; 24(3):484-90.
-
Friedberg JW, Fisher RI. Diffuse large B-cell NHL. Cancer Treat Res. 2006; 131:121-40.
-
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 Nov; 46(11):1569-73.
-
Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Braziel RM, Miller TP. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 2006 Feb 1; 107(3):1101-7.
-
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005 Nov 20; 23(33):8447-52.
-
Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005 Oct 20; 23(30):7565-73.
-
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005 Nov 1; 106(9):3183-90.
-
Fisher RI. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol. 2005 Jul; 3(7):544-6.
-
Fisher RI. Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2005 Jul; 3(7):544-6.
-
Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S, Jiang Q, Nacheva E, Yagan D, Davis E, Galiegue-Zouitina S, Catovsky D, Grogan T, Fisher RI, Miele L, Coignet LJ. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res. 2005 Jun 1; 65(11):4554-61.
-
Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005 Apr 1; 23(10):2215-23.
-
Fisher RI. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. J Clin Oncol. 2005 Feb 1; 23(4):657-8.
-
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004 Nov 18; 351(21):2159-69.
-
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004 Nov 1; 22(21):4302-11.
-
Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004 Aug 23; 23(38):6524-34.
-
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1; 104(5):1258-65.
-
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004 Jun 1; 103(11):4251-8.
-
Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004 Feb; 4(1):18-26.
-
Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 221-36.
-
Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia. 2003 Oct; 17(10):1948-60.
-
Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, McCarthy PL, Vose J, Warren L, Watt R. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2003 Oct; 9(10):667.
-
Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol. 2003 Sep 15; 21(18):3512-9.
-
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15; 198(6):851-62.
-
Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003 Aug; 9(8):529-39.
-
Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003 Jul 1; 21(13):2466-73.
-
Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003 May 15; 21(10):1996-2003.
-
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003 Sep 1; 102(5):1606-12.
-
Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol. 2003 Apr; 30(2 Suppl 4):3-9.
-
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15; 21(4):607-14.
-
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003 Feb; 3(2):185-97.
-
Fisher RI. Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity. J Clin Oncol. 2002 Nov 15; 20(22):4411-2.
-
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20; 346(25):1937-47.
-
Godwin JE, Fisher RI. Diffuse large-cell lymphomas: a review of therapy. Clin Lymphoma. 2001 Dec; 2(3):155-63.
-
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15; 19(22):4238-44.
-
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol. 2001 Jul 1; 19(13):3194-202.
-
Fisher RI. Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting. Clin Cancer Res. 2001 Jul; 7(7):1835-6.
-
Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, Unger J, Miller TP, Tubbs R, Leith C, Fisher RI, Grogan TM. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001 Jun 15; 97(12):3713-20.
-
Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol. 2001 Feb 1; 19(3):750-5.
-
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001 Jan 15; 19(2):389-97.
-
Fisher RI. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. J Natl Cancer Inst. 2001 Jan 3; 93(1):4-5.
-
Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, Vose J, Warren L, Watt R, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2001; 7(6):308-31.
-
Fisher RI. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Semin Oncol. 2000 Dec; 27(6 Suppl 12):2-8.
-
Taylor CW, LeBlanc M, Fisher RI, Moore DF, Roach RW, Elias L, Miller TP. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anticancer Drugs. 2000 Oct; 11(9):695-700.
-
Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000 May; 18(10):2010-6.
-
Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S55-7.
-
Fisher RI. Diffuse large-cell lymphoma. Ann Oncol. 2000; 11 Suppl 1:29-33.
-
Rizzo P, Carbone M, Fisher SG, Matker C, Swinnen LJ, Powers A, Di Resta I, Alkan S, Pass HI, Fisher RI. Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. Chest. 1999 Dec; 116(6 Suppl):470S-473S.
-
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul; 17(7):2105-16.
-
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr; 17(4):1244.
-
Moore DF, Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI. Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial. Invest New Drugs. 1999; 17(2):169-72.
-
Gale RP, Park RE, Dubois R, Bierman PJ, Fisher RI, Loh KK, Peterson BA, Phillips GL, Portlock CS, Rosenblum D, Armitage JO. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):139-49.
-
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 Nov 19; 339(21):1506-14.
-
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 2; 339(1):21-6.
-
Fisher RI, Miller TP, Grogan TM. New REAL clinical entities. Cancer J Sci Am. 1998 Jul; 4 Suppl 2:S5-12.
-
Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998 Mar; 16(3):818-29.
-
Fisher RI. Relapse after successful treatment with immunotherapy: lessons for the future. Cancer J Sci Am. 1998 Mar-Apr; 4(2):78-9.
-
Winter JN, Andersen J, Reed JC, Krajewski S, Variakojis D, Bauer KD, Fisher RI, Gordon LI, Oken MM, Jiang S, Jeffries D, Domer P. BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood. 1998 Feb 15; 91(4):1391-8.
-
Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher RI. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol. 1998 Feb; 16(2):574-8.
-
Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan; 16(1):19-26.
-
Fisher RI. Treatment of grey zone lymphomas. Ann Oncol. 1998; 9 Suppl 5:S121-3.
-
Gaynor ER, Fisher RI. CHOP therapy: has shorter-course therapy had an impact on lymphomas? Cancer Invest. 1998; 16(1):26-32.
-
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan; 16(1):48-55.
-
Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S70-2.
-
Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S73-8.
-
Grogan TM, Miller TP, Fisher RI. A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. Hematol Oncol Clin North Am. 1997 Oct; 11(5):819-46.
-
Miller TP, LeBlanc M, Grogan TM, Fisher RI. Follicular lymphomas: do histologic subtypes predict outcome? Hematol Oncol Clin North Am. 1997 Oct; 11(5):893-900.
-
Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997 May-Jun; 3(3):157-62.
-
Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res. 1997 Apr; 3(4):565-72.
-
Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res. 1997 Jan; 3(1):39-46.
-
Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 1997; 40 Suppl:S42-6.
-
Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Armitage JO. Lymphoma classification--the gap between biology and clinical management is closing. Blood. 1996 Dec 1; 88(11):4085-9.
-
Winter JN, Andersen J, Variakojis D, Gordon LI, Fisher RI, Oken MM, Neiman RS, Jiang S, Bauer KD. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood. 1996 Nov 15; 88(10):3919-25.
-
Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996 Aug; 14(8):2410-1.
-
Fisher RI. Report of workshop 5: early high-dose chemotherapy. Ann Oncol. 1996; 7 Suppl 4:131-3.
-
Fisher RI. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol. 1996; 7 Suppl 6:S35-9.
-
Gaynor ER, Fisher RI. Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? Oncology (Williston Park). 1995 Dec; 9(12):1273-9; discussion 1283-4.
-
Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995 Nov 1; 86(9):3333-40.
-
Sosman JA, Bartemes K, Offord KP, Kita H, Fisher SG, Kefer C, Ellis TA, Fisher RI, Higgins TJ, Gleich GJ. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995 Aug; 1(8):805-12.
-
Sosman JA, Kefer C, Fisher RI, Jacobs CD, Pumfery P, Ellis TM. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients. J Immunother Emphasis Tumor Immunol. 1995 Apr; 17(3):171-80.
-
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995 Mar; 13(3):688-96.
-
Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995 Feb 15; 85(4):1075-82.
-
Fisher RI, Oken MM. Clinical practice guidelines: non-Hodgkin's lymphomas. Cleve Clin J Med. 1995; 62 Suppl 1:SI6-42, quiz SI43-5.
-
Alzona M, Jäck HM, Fisher RI, Ellis TM. IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells. J Immunol. 1995 Jan 1; 154(1):9-16.
-
Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol. 1994 Dec; 12(12):2667-76.
-
Fisher RI. Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years. Cancer. 1994 Nov 1; 74(9 Suppl):2657-61.
-
Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol. 1994 Oct; 12(10):2153-9.
-
Alzona M, Jäck HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994 Oct 1; 153(7):2861-7.
-
Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol. 1994 Oct; 16(3):216-23.
-
Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994 Aug; 12(8):1553-60.
-
Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994 Jun 1; 120(11):903-12.
-
Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol. 1994 May; 5(5):447-52.
-
Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman CA, Fisher RI. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. Hematol Oncol. 1994 Mar-Apr; 12(2):75-85.
-
Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):147-53.
-
Nand S, Sosman J, Godwin JE, Fisher RI. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood. 1994 Jan 15; 83(2):357-60.
-
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994; 5 Suppl 2:91-5.
-
Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al. A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol. 1994 Jan; 15(1):74-8.
-
Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993 Oct; 11(10):1969-77.
-
Ellis TM, Simms PE, Slivnick DJ, Jäck HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993 Sep 1; 151(5):2380-9.
-
Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, et al. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol. 1993 Aug; 11(8):1496-505.
-
Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertens. 1993 Jul; 2(4):670-8.
-
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8; 328(14):1002-6.
-
Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993 Apr; 11(4):661-70.
-
Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993 Apr; 11(4):644-51.
-
Poplin E, Fleming T, MacDonald JS, Eisenberg P, Fisher RI, Conrad ME. Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study. Invest New Drugs. 1993 Feb; 11(1):47-51.
-
McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. Cancer Res. 1992 Nov 15; 52(22):6318-22.
-
Maecker HT, Jokinen DM, Fisher RI. T cell receptor expression can switch on and off at a posttranslational level. J Immunol. 1992 Sep 1; 149(5):1619-25.
-
Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher SG, Fisher RI. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Semin Oncol. 1992 Jun; 19(3 Suppl 9):102-9.
-
Bayer RA, Gaynor ER, Fisher RI. Bleomycin in non-Hodgkin's lymphoma. Semin Oncol. 1992 Apr; 19(2 Suppl 5):46-52; discussion 52-3.
-
Nand S, Ellis T, Messmore H, Fisher SG, Gaynor E, Fisher RI. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Leukemia. 1992 Mar; 6(3):220-3.
-
Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst. 1992 Feb 19; 84(4):256-60.
-
Gaynor ER, Fisher RI. Chemotherapy and combined modality treatment in Hodgkin's disease. Curr Opin Oncol. 1991 Oct; 3(5):822-9.
-
Gaynor ER, Fisher RI. Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):12-7.
-
Stiff PJ, McKenzie RS, Potempa LD, Albain K, Koch D, Braud E, Bansal VK, Weidner MK, Lanzotti VJ, Chun HG, et al. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study. J Clin Oncol. 1991 Aug; 9(8):1487-94.
-
Miller TP, Dahlberg S, Salmon SE, Williamson SK, Belt RJ, Dana BW, Fisher RI. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul; 9(7):1204-9.
-
Margolin KA, Aronson FR, Sznol M, Atkins MB, Ciobanu N, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ, et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother (1991). 1991 Jun; 10(3):214-20.
-
Dahlberg S, Miller TP, Fisher RI. A clinical phase II study of ProMACE-CytaBOM. J Clin Oncol. 1991 May; 9(5):888.
-
Weick JK, Dahlberg S, Fisher RI, Dana B, Miller TP, Balcerzak SP, Pierce HI. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J Clin Oncol. 1991 May; 9(5):748-53.
-
Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol. 1991 Apr; 9(4):641-8.
-
Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Ann Oncol. 1991 Jan; 2 Suppl 1:33-5.
-
Dabich L, Dahlberg S, Hartsock RJ, LoBuglio AF, Liepman MK, Grozea PN, Eyre HJ, Weick JK, Bonnet JD, Coltman CA, et al. Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest. 1991; 9(6):613-20.
-
Landis RC, Friedman ML, Fisher RI, Ellis TM. Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals. J Immunol. 1991 Jan 1; 146(1):128-35.
-
Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991 Jan; 9(1):25-38.
-
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990 Dec 20; 323(25):1723-8.
-
Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system. Semin Oncol. 1990 Dec; 17(6):673-82.
-
Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol. 1990 Dec; 8(12):1951-8.
-
Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol. 1990 Oct; 8(10):1630-6.
-
Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst. 1990 Sep 5; 82(17):1397-402.
-
Sobotka PA, McMannis J, Fisher RI, Stein DG, Thomas JX. Effects of interleukin 2 on cardiac function in the isolated rat heart. J Clin Invest. 1990 Sep; 86(3):845-50.
-
Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol. 1990 Jul; 8(7):1138-47.
-
Dana BW, Dahlberg S, Miller TP, Hartsock RJ, Balcerzak S, Coltman CA, Carden JO, Hartley K, Fisher RI. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol. 1990 Jul; 8(7):1155-62.
-
Nand S, Messmore H, Fisher SG, Bird ML, Schulz W, Fisher RI. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990 May; 34(1):32-6.
-
Fisher RI, Stiff PJ. Treatment options for recurrent lymphomas. Semin Oncol. 1990 Apr; 17(2 Suppl 4):63-7.
-
Weisfuse IB, Graham DJ, Will M, Parkinson D, Snydman DR, Atkins M, Karron RA, Feinstone S, Rayner AA, Fisher RI, et al. An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. J Infect Dis. 1990 Apr; 161(4):647-52.
-
Fisher RI. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma. Important Adv Oncol. 1990; 217-25.
-
Albain KS, Swinnen LJ, Erickson LC, Stiff PJ, Fisher RI. Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model. Cancer Chemother Pharmacol. 1990; 27(1):33-40.
-
Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol. 1989 Dec 15; 143(12):4282-6.
-
Gaynor ER, Fisher RI. Recent advances in the management of non-Hodgkin's lymphomas. Dis Mon. 1989 Sep; 35(9):597-650.
-
Longo DL, Glatstein E, Duffey PL, Ihde DC, Hubbard SM, Fisher RI, Jaffe ES, Gilliom M, Young RC, DeVita VT. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol. 1989 Sep; 7(9):1295-302.
-
Fisher RI. Picking winners and losers in diffuse small-cell lymphomas. J Clin Oncol. 1989 Aug; 7(8):991-2.
-
Slivnick DJ, Nawrocki JF, Fisher RI. Immunology and cellular biology of Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):205-20.
-
Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989 Apr 15; 142(8):2949-54.
-
Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989 Apr; 7(4):486-98.
-
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989 Apr; 7(4):477-85.
-
Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fisher RI, Erickson LC. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res. 1989 Mar 15; 49(6):1383-9.
-
Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen II, Bhoopalam N, Jassak PF, Cahill MA, Canzoneri CL, Fisher RI. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol. 1989 Feb; 7(2):276-84.
-
Futscher BW, Micetich KC, Barnes DM, Fisher RI, Erickson LC. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun. 1989; 1(1):65-73.
-
Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, Thomas JX, Fisher SG, Fisher RI. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988 Dec 15; 109(12):953-8.
-
Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res. 1988 Nov 15; 48(22):6597-602.
-
Ellis TM, McMannis JD, Chua AO, Gubler U, Fisher RI. Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity. Cell Immunol. 1988 Oct 15; 116(2):352-66.
-
Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol. 1988 Jul 15; 141(2):672-80.
-
Kozeny GA, Nicolas JD, Creekmore S, Sticklin L, Hano JE, Fisher RI. Effects of interleukin-2 immunotherapy on renal function. J Clin Oncol. 1988 Jul; 6(7):1170-6.
-
Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr; 108(4):518-23.
-
Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1988 Apr; 25(2 Suppl 2):17-22.
-
McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol. 1988 Feb 15; 140(4):1335-40.
-
Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987 Dec; 5(12):1998-2003.
-
Stiff PJ, Koester AR, Weidner MK, Dvorak K, Fisher RI. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood. 1987 Oct; 70(4):974-8.
-
Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987 Apr; 24(2 Suppl 1):21-5.
-
Nand S, Messmore HL, Patel R, Fisher SG, Fisher RI. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol. 1986 Apr; 4(4):571-5.
-
Nagai H, Fisher RI, Cossman J, Oppenheim JJ. Decreased expression of class II major histocompatibility antigens on monocytes from patients with Hodgkin's disease. J Leukoc Biol. 1986 Mar; 39(3):313-21.
-
Boccia RV, Longo DL, Lieber ML, Jaffe ES, Fisher RI. Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. Cancer. 1985 Nov 1; 56(9):2295-7.
-
Fisher RI, Cossman J, Diehl V, Volkman DJ. Antigen presentation by Hodgkin's disease cells. J Immunol. 1985 Nov; 135(5):3568-71.
-
Hecht TT, Longo DL, Cossman J, Bolen JB, Hsu SM, Israel M, Fisher RI. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol. 1985 Jun; 134(6):4231-6.
-
Geffen DB, Fisher RI, Longo DL, Young RC, DeVita VT. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. J Clin Oncol. 1985 May; 3(5):646-53.
-
Fisher RI, Young RC, Longo D, DeVita VT. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Semin Oncol. 1985 Mar; 12(1 Suppl 2):29-32.
-
Silver BA, Bostick-Bruton FW, Neckers L, Fisher RI. Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas. Cancer. 1984 Dec 15; 54(12):2936-42.
-
Cossman J, Jaffe ES, Fisher RI. Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features. Cancer. 1984 Oct 1; 54(7):1310-7.
-
Fisher RI, Bates SE, Bostick-Bruton F, Tuteja N, Diehl V. Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses. J Immunol. 1984 May; 132(5):2672-7.
-
Longo DL, Young RC, Hubbard SM, Wesley M, Fisher RI, Jaffe E, Berard C, DeVita VT. Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med. 1984 May; 100(5):651-6.
-
Shackney SE, Levine AM, Fisher RI, Nichols P, Jaffe E, Schuette WH, Simon R, Smith CA, Occhipinti SJ, Parker JW, et al. The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases. J Clin Invest. 1984 Apr; 73(4):1201-14.
-
Cossman J, Chused TM, Fisher RI, Magrath I, Bollum F, Jaffe ES. Diversity of immunological phenotypes of lymphoblastic lymphoma. Cancer Res. 1983 Sep; 43(9):4486-90.
-
Blayney DW, Blattner WA, Robert-Guroff M, Jaffe ES, Fisher RI, Bunn PA, Patton MG, Rarick HR, Gallo RC. The human T-cell leukemia-lymphoma virus in the southeastern United States. JAMA. 1983 Aug 26; 250(8):1048-52.
-
Gallo RC, Kalyanaraman VS, Sarngadharan MG, Sliski A, Vonderheid EC, Maeda M, Nakao Y, Yamada K, Ito Y, Gutensohn N, Murphy S, Bunn PA, Catovsky D, Greaves MF, Blayney DW, Blattner W, Jarrett WF, zur Hausen H, Seligmann M, Brouet JC, Haynes BF, Jegasothy BV, Jaffe E, Cossman J, Broder S, Fisher RI, Golde DW, Robert-Guroff M. Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res. 1983 Aug; 43(8):3892-9.
-
Fisher RI, Bostick-Bruton F, Sauder DN, Scala G, Diehl V. Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol. 1983 Jun; 130(6):2666-70.
-
Fisher RI, DeVita VT, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar; 98(3):304-9.
-
Fisher RI. Non-Hodgkin's lymphomas after treatment of Hodgkin's disease. Arch Intern Med. 1983 Mar; 143(3):427.
-
Blayney DW, Jaffe ES, Fisher RI, Schechter GP, Cossman J, Robert-Guroff M, Kalyanaraman VS, Blattner WA, Gallo RC. The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia. Ann Intern Med. 1983 Feb; 98(2):144-51.
-
Thomas JL, Bernardino ME, Vermess M, Barnes PA, Fuller LM, Hagemeister FB, Doppman J, Fisher RI, Longo DL. EOE-13 in the detection of hepatosplenic lymphoma. Radiology. 1982 Dec; 145(3):629-34.
-
Fisher RI, Bostick-Bruton F. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. J Immunol. 1982 Oct; 129(4):1770-4.
-
Vermess M, Doppman JL, Sugarbaker PH, Fisher RI, O'Leary TJ, Chatterji DC, Grimes G, Adamson RH, Willis M, Edwards BK. Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations. AJR Am J Roentgenol. 1982 Jun; 138(6):1063-71.
-
Fisher RI, Silver BA, Vanhaelen CP, Jaffe ES, Cossman J. Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin. Cancer Res. 1982 Jun; 42(6):2465-9.
-
Silver BA, Barlock AL, Lippman ME, Anderson T, Fisher RI. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. Cancer Treat Rep. 1982 May; 66(5):1229-30.
-
Fisher RI. Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease. Cancer Treat Rep. 1982 Apr; 66(4):681-7.
-
Vanhaelen CP, Fisher RI. Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease. Am J Med. 1982 Mar; 72(3):385-90.
-
Levine AS, Brennan MF, Ramu A, Fisher RI, Pizzo PA, Glaubiger DL. Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance. Cancer Res. 1982; 42(2 Suppl):774s-781s.
-
Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, Fisher SG. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am. 1981 Dec; 61(6):1267-77.
-
Micetich KC, Jensen-Akula M, Mandard JC, Fisher RI. Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. Am J Med. 1981 Dec; 71(6):967-72.
-
Vermess M, Bernardino ME, Doppman JL, Fisher RI, Thomas JL, Velasquez WS, Fuller LM, Russo A. Use of intravenous liposoluble contrast material for the examination of the liver and spleen in lymphoma. J Comput Assist Tomogr. 1981 Oct; 5(5):709-13.
-
Vanhaelen CP, Fisher RI. Increased sensitivity of lymphocytes from patients with Hodgkin's disease to concanavalin A-induced suppressor cells. J Immunol. 1981 Sep; 127(3):1216-20.
-
Vanhaelen CP, Fisher RI, Appella E, Ramanathan L. Lack of histocompatibility antigens on a murine ovarian teratocarcinoma. Cancer Res. 1981 Aug; 41(8):3186-91.
-
Popp MB, Fisher RI, Wesley R, Aamodt R, Brennan MF. A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. Surgery. 1981 Aug; 90(2):195-203.
-
Ozols RF, Fisher RI, Anderson T, Makuch R, Young RC. Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol. 1981 Jul 15; 140(6):611-9.
-
Fisher RI, Hubbard SM, DeVita VT, Berard CW, Wesley R, Cossman J, Young RC. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood. 1981 Jul; 58(1):45-51.
-
Fisher RI, Vanhaelen C, Bostick F. Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkin's disease. Blood. 1981 May; 57(5):830-5.
-
Fisher RI, Jones RB, DeVita VT, Simon RM, Garvin AJ, Berard CW, Young RC. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer. 1981 Apr 15; 47(8):2022-5.
-
Vanhaelen CP, Fisher RI. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer. Cancer Res. 1981 Mar; 41(3):980-3.
-
Popp MB, Fisher RI, Simon RM, Brennan MF. A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. Cancer Treat Rep. 1981; 65 Suppl 5:129-35.
-
Vermess M, Doppman JL, Sugarbaker P, Fisher RI, Chatterji DC, Luetzeler J, Grimes G, Girton M, Adamson RH. Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen. Radiology. 1980 Oct; 137(1 Pt 1):217-22.
-
Morens DM, Bregman DJ, West CM, Greene MH, Mazur MH, Dolin R, Fisher RI. An outbreak of varicella-zoster virus infection among cancer patients. Ann Intern Med. 1980 Sep; 93(3):414-9.
-
Chabner BA, Fisher RI, Young RC, DeVita VT. Staging of non-Hodgkin's lymphoma. Semin Oncol. 1980 Sep; 7(3):285-91.
-
Dunnick NR, Fisher RI, Chu EW, Young RC. Percutaneous aspiration of retroperitoneal lymph nodes in ovarian cancer. AJR Am J Roentgenol. 1980 Jul; 135(1):109-13.
-
Fisher RI, DeVita VT, Bostick F, Vanhaelen C, Howser DM, Hubbard SM, Young RC. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med. 1980 May; 92(5):595-9.
-
Fisher RI, Mandell GL, Bostick F, McMenamin MG, Anderson T. Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice. Clin Exp Immunol. 1980 Feb; 39(2):416-25.
-
Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC. Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res. 1979 Aug; 39(8):3202-8.
-
Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med. 1979 May; 90(5):761-3.
-
Mandell GL, Fisher RI, Bostick F, Young RC. Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function. Am J Med. 1979 Apr; 66(4):621-4.
-
Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, DeVita VT. Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med. 1979 Mar; 66(3):435-43.
-
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, Young RC. Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. Cancer Treat Rep. 1979 Feb; 63(2):269-73.
-
Fisher RI, Chabner BA, Myers CE. Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. Cancer Treat Rep. 1979 Jan; 63(1):147-8.
-
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7; 299(23):1261-6.
-
Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer. 1978 Nov; 42(5):2157-61.
-
Young RC, Fisher RI. The staging and treatment of epithelial ovarian cancer. Can Med Assoc J. 1978 Aug 12; 119(3):249-56.
-
Fisher RI, Kubota TT, Mandell GL, Broder S, Young RC. Regression of a T-cell lymphoma after administration of antithymocyte globulin. Ann Intern Med. 1978 Jun; 88(6):799-800.
-
Young NA, Kwon-Chung KJ, Kubota TT, Jennings AE, Fisher RI. Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. J Clin Microbiol. 1978 Jun; 7(6):589-94.
-
Hande KR, Fisher RI, DeVita VT, Chabner BA, Young RC. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer. 1978 May; 41(5):1984-9.
-
Fisher RI, Young RC. Chemotherapy of ovarian cancer. Surg Clin North Am. 1978 Feb; 58(1):143-50.
-
Bender RA, Anderson T, Fisher RI, Young RC. Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. Am J Hematol. 1978; 5(3):203-9.
-
Hande KR, Reimer RR, Fisher RI. Comparison of nodal primary versus extranodal primary histiocytic lymphoma. Cancer Treat Rep. 1977 Sep; 61(6):999-1000.
-
Anderson T, Bender RA, Fisher RI, DeVita VT, Chabner BA, Berard CW, Norton L, Young RC. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep. 1977 Sep; 61(6):1057-66.
-
DeVita VT, Fisher RI. Malignant melanoma: prognostic factors and therapeutic results. W V Med J. 1977 Aug; 73(8):167-72.
-
Fisher RI, DeVita VT, Johnson BL, Simon R, Young RC. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med. 1977 Aug; 63(2):177-82.
-
Fisher RI, Young RC. Advances in the staging and treatment of ovarian cancer. Cancer. 1977 Feb; 39(2 Suppl):967-72.
-
Fisher RI, Jaffe ES, Braylan RC, Andersen JC, Tan HK. Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features. Am J Med. 1976 Oct; 61(4):553-9.
-
Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet. 1976 Aug 14; 2(7981):337-9.
-
DeVita VT, Fisher RI. Natural history of malignant melanoma as related to therapy. Cancer Treat Rep. 1976 Feb; 60(2):153-7.
-
Neifeld JP, Lippman ME, Fisher RI. Receptors for steroid hormones in human melanoma. Surg Forum. 1976; 27(62):108-10.
-
Henkart PA, Fisher RI. Characterization of the lymphocyte surface receptors for Con A and PHA. J Immunol. 1975 Feb; 114(2 Pt 1):710-4.
-
Fisher RI. Cognitive appraisal: an examination. J Psychol. 1974 Sep; 88(1st Half):147-52.
-
Dickler HB, Adkinson NF, Fisher RI, Terry WD. Lymphocytes in patients with variable immunodeficiency and panhypogammaglobulinemia. Evaluation of B and T cell surface markers and a proposed classification. J Clin Invest. 1974 Mar; 53(3):834-40.
|
Fisher's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
